Clinical development

References

1. ^^abcGRCh38: Ensembl release 89: ENSG00000081041 –Ensembl, May 2017
2. ^^abcGRCm38: Ensembl release 89: ENSMUSG00000029380 –Ensembl, May 2017
3. ^"Human PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
4. ^"Mouse PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
5. ^Wolpe SD, Sherry B, Juers D, Davatelis G, Yurt RW, Cerami A (January 1989)."Identification and characterization of macrophage inflammatory protein 2".Proceedings of the National Academy of Sciences of the United States of America.86 (2):612–6.Bibcode:1989PNAS...86..612W.doi:10.1073/pnas.86.2.612.PMC 286522.PMID 2643119.
6. ^Iida N, Grotendorst GR (October 1990)."Cloning and sequencing of a new gro transcript from activated human monocytes: expression in leukocytes and wound tissue".Molecular and Cellular Biology.10 (10):5596–9.doi:10.1128/mcb.10.10.5596.PMC 361282.PMID 2078213.
7. ^^abPelus LM, Fukuda S (August 2006)."Peripheral blood stem cell mobilization: the CXCR2 ligand GRObeta rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties".Experimental Hematology.34 (8):1010–20.doi:10.1016/j.exphem.2006.04.004.PMID 16863907.
8. ^O'Donovan N, Galvin M, Morgan JG (1999). "Physical mapping of the CXC chemokine locus on human chromosome 4".Cytogenetics and Cell Genetics.84 (1–2):39–42.doi:10.1159/000015209.PMID 10343098.S2CID 8087808.
9. ^^abAl-Alwan LA, Chang Y, Mogas A,Halayko AJ, Baglole CJ, Martin JG, et al. (September 2013)."Differential roles of CXCL2 and CXCL3 and their receptors in regulating normal and asthmatic airway smooth muscle cell migration".Journal of Immunology.191 (5):2731–41.doi:10.4049/jimmunol.1203421.PMC 3748335.PMID 23904157.
10. ^Hoggatt J, Singh P, Tate TA, Chou BK, Datari SR, Fukuda S, et al. (January 2018)."Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell".Cell.172 (1–2): 191–204.e10.doi:10.1016/j.cell.2017.11.003.PMC 5812290.PMID 29224778.
11. ^Clinical trial numberNCT04762875 for "A Phase II Study Evaluating the Safety and Efficacy of MGTA-145 in Combination With Plerixafor for the Mobilization and Transplantation of HLA-Matched Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies" atClinicalTrials.gov
12. ^Clinical trial numberNCT04552743 for "Phase II Study of MGTA-145 in Combination With Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Patients With Multiple Myeloma" atClinicalTrials.gov
13. ^"Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at the American Society of Clinical Oncology (ASCO) Annual Meeting – Magenta Therapeutics".investor.magentatx.com. Retrieved2021-10-22.^{[permanent dead link]}